featured
Pembrolizumab Plus Chemotherapy as a First-Line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
J. Clin. Oncol 2023 Nov 01;[EPub Ahead of Print], BJ Monk, N Colombo, KS Tewari, C Dubot, MV Caceres, K Hasegawa, R Shapira-Frommer, P Salman, E Yañez, M Gümüş, M Olivera Hurtado de Mendoza, V Samouëlian, V Castonguay, A Arkhipov, C Tekin, K Li, SM Keefe, D LorussoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.